In particular, these authors underlined how the increased CDK6 expression observed in resistant cells is dependent on TGF-b pathway suppression via miR-432-5p expression; in particular, they found that levels of miR-432-5p are higher in primary breast cancers, so far demonstrating CDK4/6 resistance compared to those that are sensitive. Here, CDK4 is linked to breast carcinoma.